Table 2.
DMARD usage at ARAD enrolment (n = 4140)
| Number | Percentage | |
|---|---|---|
| Biologic use | ||
| Never taken | 1525 | 36.8 |
| Currently taking anti-TNF biologics | 2350 | 56.8 |
| Currently taking other biologics | 128 | 3.1 |
| Abatacept | 32 | 0.8 |
| Anakinra | 7 | 0.2 |
| Rituximab | 66 | 1.6 |
| Tocilizumab | 23 | 0.6 |
| Previous use | 121 | 2.9 |
| Unknowna | 16 | 0.4 |
| Methotrexate status | ||
| Never taken | 977 | 23.6 |
| Currently taking | 2302 | 55.6 |
| Stopped taking | 856 | 20.7 |
| Unknowna | 5 | 0.1 |
| Prednisone/prednisolone status | ||
| Never taken | 1529 | 36.9 |
| Currently taking | 1613 | 39.0 |
| Stopped taking | 969 | 23.4 |
| Unknowna | 29 | 0.7 |
| NSAID status | ||
| Not currently taking | 2011 | 48.6 |
| Currently taking | 2129 | 51.4 |
ARAD Australian Rheumatology Association Database, DMARD disease-modifying anti-rheumatic drug, TNF tumour necrosis factor, NSAID non-steroidal anti-inflammatory drug
aParticipant reports that they do not know, or are unsure of the answer